ARID1A and neoplasm: The median progression-free survival of patients with altered ARID1A was significantly longer than that of patients with wild-type ARID1A in terms of response to ICB therapy, regardless of microsatellite instability (MSI) and tumor mutation burden (TMB) statuses.